Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Triumvira Immunologics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11089
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Triumvira Immunologics Inc (Triumvira) is a biopharmaceutical company developing engineered T cell therapies for the treatment of multiple cancers. Its proprietary immuno-oncology platform T cell Antigen Coupler (TAC), enables natural T cell receptor to induce a controlled, tumor-specific response with reduced toxicities and thus eliminates solid tumors. The company’s lead product candidate CD19-TAC01, is targeted for the treatment of CD19 positive B-cell malignancies such as Diffuse Large B Cell Lymphoma (DLBCL). Triumvira seeks to work in partnership with other pharmaceutical companies for collaboration and licensing opportunities of its TAC technology platform. The company has operations with research facilities in Hamilton, Canada. Triumvira is headquartered in Austin, Texas, the US.

Triumvira Immunologics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Triumvira Immunologics Raises USD1.4 Million in Seed Financing Round 10
Licensing Agreements 11
Centre for Commercialization of Cancer Immunotherapy Enters into Licensing Agreement with Triumvira Immunologics 11
Triumvira Immunologics Enters into Licensing Agreement with McMaster University 12
Triumvira Immunologics Inc – Key Competitors 13
Triumvira Immunologics Inc – Key Employees 14
Triumvira Immunologics Inc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 16
Corporate Communications 16
Jun 25, 2018: Triumvira Immunologics Names Scott Smith As Board Director 16
Jun 11, 2018: Triumvira Names Donna Rill As Chief Technology Officer 17
Apr 05, 2018: Triumvira Immunologics Appoints Cynthia Collins to Board of Directors 18
Jan 04, 2018: Paul Lammers, M.D., M.Sc. Joins Triumvira as President and Chief Executive Officer 19
Product News 20
Aug 03, 2018: Nature Communications publishes studies comparing Triumvira’s T cell antigen coupler (TAC) technology with CAR T cell therapy 20
04/30/2018: Triumvira Immunologics to Present at Two Upcoming Conferences: International Society for Cellular Therapy and Bloom Burton & Co. Healthcare Investor Conference 21
03/22/2018: Triumvira Immunologics to Present at the 25th BioCentury Future Leaders Conference 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Triumvira Immunologics Raises USD1.4 Million in Seed Financing Round 10
Centre for Commercialization of Cancer Immunotherapy Enters into Licensing Agreement with Triumvira Immunologics 11
Triumvira Immunologics Enters into Licensing Agreement with McMaster University 12
Triumvira Immunologics Inc, Key Competitors 13
Triumvira Immunologics Inc, Key Employees 14
Triumvira Immunologics Inc, Other Locations 15

List of Figures
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Triumvira Immunologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Schouw & Co. A/S:戦略・SWOT・企業財務分析
    Schouw & Co. A/S - Strategy, SWOT and Corporate Finance Report Summary Schouw & Co. A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Zoo Digital Group plc (ZOO):企業の財務・戦略的SWOT分析
    Summary Zoo Digital Group Plc (ZOO) is a technology company that offers localization and media production services. The company offers services such as subtitling, captioning, dubbing and digital distribution. Its activities include providing a range of services to allow television and movie content …
  • Total SA (FP)-石油・ガス分野:企業M&A・提携分析
    Summary Total S.A. (Total) is an integrated global oil and gas company that produces, refines and markets oil, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distribution of petrole …
  • Da Afghanistan Breshna Sherkat:企業の戦略的SWOT分析
    Da Afghanistan Breshna Sherkat - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Lupin Ltd (LUPIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-int …
  • Mtr Corporation Ltd
    Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Mtr Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bio-Path Holdings Inc (BPTH):医療機器:M&Aディール及び事業提携情報
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Cell Therapy Catapult Ltd-医療機器分野:企業M&A・提携分析
    Summary Cell Therapy Catapult Ltd (Catapult) is a developer of cell and gene therapies. The company supports cell and gene therapy companies worldwide to translate early stage research into commercially sustainable and investable treatments. It offers non-clinical safety, clinical trials, regulation …
  • Hensel Phelps Construction Co:企業の戦略的SWOT分析
    Hensel Phelps Construction Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Xencor, Inc.:企業のM&A・事業提携・投資動向
    Xencor, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Xencor, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Innocoll AG (INNL)-医療機器分野:企業M&A・提携分析
    Summary Innocoll AG (Innocoll), formerly Innocoll Holdings Inc is a specialty pharmaceutical company that carries out the development and manufacturing of surgical implants and topically applied healthcare products in the areas of unmet clinical needs. The company’s pipeline product portfolio includ …
  • GSI Technology, Inc. (GSIT):企業の財務・戦略的SWOT分析
    GSI Technology, Inc. (GSIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • The Mauritius Commercial Bank Limited
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Netcare Ltd (NTC):企業の財務・戦略的SWOT分析
    Summary Netcare Ltd (Netcare) is a healthcare service provider that offers patient care services. The center provides medical facilities and treatments in the fields of breast care, oncology, orthopedics, renal care, transplants and weight management. Its facilities include medicross centers, netcar …
  • Singapore Power Ltd:企業の戦略的SWOT分析
    Singapore Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • BioTime Inc (BTX):企業の製品パイプライン分析2018
    Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also develo …
  • Diebold Nixdorf AG.:企業の戦略・SWOT・財務分析
    Diebold Nixdorf AG. - Strategy, SWOT and Corporate Finance Report Summary Diebold Nixdorf AG. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • CivaTech Oncology Inc-医療機器分野:企業M&A・提携分析
    Summary CivaTech Oncology Inc (CivaTech) is a medical device company that provides radiation therapy solutions. The company develops polymer based low dose rate (LDR) brachytherapy devices for the treatment of cancer. Its product portfolio includes CivaString, a radiation therapy device to treat sol …
  • David Lloyd Leisure Ltd:企業の戦略・SWOT・財務情報
    David Lloyd Leisure Ltd - Strategy, SWOT and Corporate Finance Report Summary David Lloyd Leisure Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Colabor Group Inc (GCL):企業の財務・戦略的SWOT分析
    Colabor Group Inc (GCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆